[go: up one dir, main page]

WO2012050393A3 - 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 - Google Patents

리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 Download PDF

Info

Publication number
WO2012050393A3
WO2012050393A3 PCT/KR2011/007667 KR2011007667W WO2012050393A3 WO 2012050393 A3 WO2012050393 A3 WO 2012050393A3 KR 2011007667 W KR2011007667 W KR 2011007667W WO 2012050393 A3 WO2012050393 A3 WO 2012050393A3
Authority
WO
WIPO (PCT)
Prior art keywords
reverse
production method
novel compound
turn mimetic
use therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/007667
Other languages
English (en)
French (fr)
Other versions
WO2012050393A2 (ko
Inventor
정재욱
김미정
이용실
마상호
조영석
이상학
나영준
강명주
박월성
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JW Pharmaceutical Corp
Original Assignee
JW Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JW Pharmaceutical Corp filed Critical JW Pharmaceutical Corp
Priority to EP11832780.8A priority Critical patent/EP2628741B1/en
Priority to KR1020137006430A priority patent/KR101892575B1/ko
Priority to US13/878,990 priority patent/US8940739B2/en
Priority to JP2013533778A priority patent/JP5809279B2/ja
Priority to ES11832780.8T priority patent/ES2552462T3/es
Priority to CN201180049821.9A priority patent/CN103209982B/zh
Publication of WO2012050393A2 publication Critical patent/WO2012050393A2/ko
Publication of WO2012050393A3 publication Critical patent/WO2012050393A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

본 발명은 피라지노트리아지논 (Pyrazino-triazinone)을 기본 구조로 갖는，리버스-턴 유사체의 신규한 화합물 및 이의 제조방법에 관한 것이고， 또한 상기 화합물의 항암효과 등의 질병치료제， 특히 급성 골수성 백혈병의 치료제로서의 용도에 관한 것이다.
PCT/KR2011/007667 2010-10-14 2011-10-14 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 Ceased WO2012050393A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP11832780.8A EP2628741B1 (en) 2010-10-14 2011-10-14 Novel compound of a reverse-turn mimetic and a production method and use therefor
KR1020137006430A KR101892575B1 (ko) 2010-10-14 2011-10-14 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
US13/878,990 US8940739B2 (en) 2010-10-14 2011-10-14 Compound of a reverse-turn mimetic and a production method and use therefor
JP2013533778A JP5809279B2 (ja) 2010-10-14 2011-10-14 リバースターン類似体の新規な化合物およびその製造方法と用途
ES11832780.8T ES2552462T3 (es) 2010-10-14 2011-10-14 Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
CN201180049821.9A CN103209982B (zh) 2010-10-14 2011-10-14 反转模拟物的化合物、其制造方法及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0100490 2010-10-14
KR20100100490 2010-10-14

Publications (2)

Publication Number Publication Date
WO2012050393A2 WO2012050393A2 (ko) 2012-04-19
WO2012050393A3 true WO2012050393A3 (ko) 2012-07-26

Family

ID=45938820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007667 Ceased WO2012050393A2 (ko) 2010-10-14 2011-10-14 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도

Country Status (8)

Country Link
US (1) US8940739B2 (ko)
EP (1) EP2628741B1 (ko)
JP (1) JP5809279B2 (ko)
KR (1) KR101892575B1 (ko)
CN (1) CN103209982B (ko)
ES (1) ES2552462T3 (ko)
TW (1) TWI531573B (ko)
WO (1) WO2012050393A2 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6059224B2 (ja) 2011-08-09 2017-01-11 ジェイダブリュ ファーマセウティカル コーポレーション ピラジノ−トリアジン誘導体を含む非小細胞性肺癌の予防および治療用組成物
US9353119B2 (en) 2011-08-09 2016-05-31 Jw Pharmaceutical Corporation Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
US9174998B2 (en) * 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
KR102496364B1 (ko) * 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN107614504B (zh) * 2015-06-23 2019-12-24 卫材R&D管理有限公司 甲酰胺化合物的晶体
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR20220000460A (ko) * 2020-06-26 2022-01-04 제이더블유중외제약 주식회사 폐섬유화증 치료용 조성물
KR20220148758A (ko) * 2021-04-29 2022-11-07 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
IL315365A (en) * 2022-03-14 2024-11-01 Purdue Research Foundation Spleen tyrosine kinase inhibitor, composition and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008941B2 (en) * 2001-05-16 2006-03-07 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
KR20100085107A (ko) * 2007-10-15 2010-07-28 주식회사 중외제약 리버스턴 유사체의 신규 화합물 및 그의 용도(3)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
AU679460B2 (en) 1992-08-06 1997-07-03 Molecumetics, Ltd. Conformationally restricted mimetics of reverse turns and peptides containing the same
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1444235B1 (en) * 2001-10-12 2008-06-11 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
KR20060121842A (ko) 2003-08-28 2006-11-29 주식회사 중외제약 β-카테닌/ＴＣＦ에 의해 활성화되는 전사의 조절
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
ES2570994T3 (es) 2005-11-08 2016-05-23 Choongwae Pharma Corp Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer
US20070128669A1 (en) 2005-11-28 2007-06-07 Institute For Chemical Genomics Serum-free expansion of cells in culture
CN101495120A (zh) 2006-05-30 2009-07-29 中外制药株式会社 用于诱导或抑制干细胞分化的组合物
CA2758904C (en) 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008941B2 (en) * 2001-05-16 2006-03-07 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
KR20100085107A (ko) * 2007-10-15 2010-07-28 주식회사 중외제약 리버스턴 유사체의 신규 화합물 및 그의 용도(3)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2628741A4 *

Also Published As

Publication number Publication date
TW201219395A (en) 2012-05-16
CN103209982B (zh) 2016-03-16
EP2628741A2 (en) 2013-08-21
EP2628741A4 (en) 2013-08-21
TWI531573B (zh) 2016-05-01
US8940739B2 (en) 2015-01-27
JP5809279B2 (ja) 2015-11-10
CN103209982A (zh) 2013-07-17
KR101892575B1 (ko) 2018-08-31
US20130196972A1 (en) 2013-08-01
KR20140020224A (ko) 2014-02-18
ES2552462T3 (es) 2015-11-30
EP2628741B1 (en) 2015-10-07
JP2013540774A (ja) 2013-11-07
WO2012050393A2 (ko) 2012-04-19

Similar Documents

Publication Publication Date Title
WO2012050393A3 (ko) 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
IL291613B2 (en) Anticoagulant monoclonal antibodies (anti–factor xii/fxiia), method for their preparation, pharmaceutical composition containing them and medical uses
WO2012138981A3 (en) New intermediates and processes for preparing ticagrelor
WO2013021279A3 (en) Highly galactosylated antibodies
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
WO2011093825A3 (en) Effervescent dosage forms comprising cephalosporin antibiotic
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2013165921A3 (en) Therapeutic use of chardonnay seed products
WO2012038504A3 (en) Breast cancer therapeutics
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2013188417A3 (en) Treatment and prevention of cardiovascular disease and thrombosis
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2010136104A3 (en) Anti-dandruff agents
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
MX339772B (es) Metodo y composicion para producir azucar clarificada.
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
IT1402643B1 (it) Corpo per pedale strumentato e procedimento di produzione dello stesso.
WO2012154879A3 (en) Autophagy inhibitors
IN2014DN03010A (ko)
WO2011088020A9 (en) Modified saponins for the treatment of fungal infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180049821.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11832780

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20137006430

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13878990

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011832780

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013533778

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE